

William C Cromwell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1249733/publications.pdf>

Version: 2024-02-01

20
papers

3,854
citations

516215

16
h-index

794141

19
g-index

21
all docs

21
docs citations

21
times ranked

4098
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level. <i>American Journal of Cardiology</i> , 2017, 119, 404-409.	0.7	9
2	Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). <i>American Journal of Cardiology</i> , 2016, 117, 1921-1927.	0.7	43
3	Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2015, 9, 201-209.	0.6	26
4	Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2178-2184.	1.2	213
5	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. <i>Journal of Clinical Lipidology</i> , 2011, 5, 133-140.	0.6	483
6	Future issues, public policy, and public awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, S46-S51.	0.6	27
7	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. <i>Journal of Clinical Lipidology</i> , 2011, 5, S1-S8.	0.6	406
8	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011, 5, 338-367.	0.6	235
9	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2010, 375, 998-1006.	6.3	813
10	Arterial Age as a Function of Coronary Artery Calcium. <i>American Journal of Cardiology</i> , 2009, 103, 1330-1331.	0.7	1
11	Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease. <i>Current Cardiology Reports</i> , 2009, 11, 468-475.	1.3	37
12	High-density lipoprotein associations with coronary heart disease: Does measurement of cholesterol content give the best result?. <i>Journal of Clinical Lipidology</i> , 2007, 1, 57-64.	0.6	10
13	LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management. <i>Journal of Clinical Lipidology</i> , 2007, 1, 583-592.	0.6	365
14	Utilization of Lipoprotein Subfractions. , 2007, , 321-347.		0
15	Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy. <i>Clinics in Laboratory Medicine</i> , 2006, 26, 847-870.	0.7	619
16	Heterogeneity of Low-Density Lipoprotein Particle Number in Patients With Type 2 Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl. <i>American Journal of Cardiology</i> , 2006, 98, 1599-1602.	0.7	68
17	Low-density lipoprotein particle number and risk for cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2004, 6, 381-387.	2.0	175
18	Measurement issues related to lipoprotein heterogeneity. <i>American Journal of Cardiology</i> , 2002, 90, 22-29.	0.7	269

#	ARTICLE	IF	CITATIONS
19	Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. American Journal of Cardiology, 2001, 87, 232-234.	0.7	30
20	Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. American Journal of Cardiology, 2000, 86, 1123-1127.	0.7	22